Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 125.53B P/E - EPS this Y 16.00% Ern Qtrly Grth -
Income -5.08B Forward P/E 7.11 EPS next Y 6.30% 50D Avg Chg -6.00%
Sales 44.38B PEG 1.16 EPS past 5Y 21.59% 200D Avg Chg -13.00%
Dividend 3.00% Price/Book 3.41 EPS next 5Y 6.72% 52W High Chg -19.00%
Recommedations 1.90 Quick Ratio 1.21 Shares Outstanding 2.22B 52W Low Chg 1.00%
Insider Own 0.06% ROA 4.31% Shares Float 2.19B Beta 0.63
Inst Own 75.30% ROE -11.76% Shares Shorted/Prior 20.83M/20.99M Price 56.49
Gross Margin 79.58% Profit Margin -11.44% Avg. Volume 9,486,338 Target Price 74.63
Oper. Margin 18.55% Earnings Date Oct 27 Volume 18,610,077 Change -3.00%
Bristol-Myers Squibb Company News
10/27/21 SHAREHOLDER ALERT: CLAIMSFILER REMINDS APPH, BMY, EAR, HEPS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
10/27/21 SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
10/27/21 Bristol Myers Skids As Looming Generics Shadow Its Biggest Product
10/27/21 Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
10/27/21 Q3 Earnings' Smooth Sailing Continues
10/27/21 Earnings Data Deluge
10/27/21 Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View
10/27/21 Bristol Myers Q3 Earnings In-line With Expectations, Raises Lower End Of FY21 Adjusted EPS Outlook
10/27/21 Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
10/27/21 Bristol Myers Squibb says sales of Revlimid, Eliquis increased in the third quarter
10/27/21 Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound
10/27/21 Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
10/26/21 FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of APPH, BMY, EAR and HNST
10/26/21 BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
10/25/21 Aurinia Rockets — Again — On Rumored Bristol Marriage; Could Others Make A Pass?
10/25/21 INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of APPH, BMY, EAR Investors, Lead Plaintiff Deadlines Set
10/25/21 Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

BMY Chatroom

User Image biotech99 Posted - 1 hour ago

$BMY might be headed under $50

User Image cyberev Posted - 1 hour ago

$PPBT Looks like $BMY is forming a bear flag just below the weekly support level. This is amazing to say the least…is something about to go down with them?

User Image biopharmphd Posted - 1 hour ago

$AUPH More context to urgency for $BMY to acquire $AUPH: -Deucravacitinib (BMS only candidate for LN) ph2 trial is going nowhere with only 15 patients recruited as of Sep21 per clinicaltrials.gov -FDA recently has been cracking down on JAK inhibitors [TYK2 inhibs(deucravacitinib) are sometimes considered another JAK]. -Deucravacitinib recently failed in UC. BMY will need to decide between investing money in chasing that indication or buying an approved product that can bring revenue now

User Image ChartMill Posted - 1 hour ago

$BMY shows a strong growth in EPS: 17.77%, which is quite good. https://www.chartmill.com/stock/quote/BMY/fundamental-analysis?key=2001b027-9d63-4fea-985c-211d9bf9cff9&utm_source=stocktwits&utm_medium=FA&utm_content=BMY&utm_campaign=social_tracking

User Image masonat Posted - 2 hours ago

$BMY becoming a higher conviction buy at these prices. A nice dividend (with a likely solid increase coming in Dec) while we wait for inevitable multiple expansion. A growing business can't stay this depressed forever.

User Image marketchameleonwins Posted - 3 hours ago

$BMY I.V. in the ATM 19-Nov-21 Falls -4.0% to 23.1. Options Imply a Move of ±4.8% with 23 Days to Exp https://tinyurl.com/y2pxy4pg

User Image ChartMill Posted - 3 hours ago

New 52 week lows for $SGFY, $CRTX and $BMY https://www.chartmill.com/stock/stock-screener?f=p_pg10,v1_50b500,s2_nl,exch_us&v=3&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_New_52_week_low_today&utm_campaign=social_tracking

User Image masonat Posted - 3 hours ago

$BMY reminds me of $ABBV. Perpetually grossly undervalued despite consistently growing earnings, revenues, and free cash flow. Market is always obsessed with patent cliffs years down the road while ignoring massive cash growth in real-time, which can be used to develop or acquire drugs to reduce the impact of said patent cliffs if needed.

User Image Stuff4less92 Posted - 4 hours ago

$BMY This stock follows this pattern a couple times every 5 years. Fear the parallel lines

User Image Utradea Posted - 4 hours ago

Bristol Myers $BMY beats Neck and throat cancer in clinical trial https://utradea.com/positions/Bristol-Myers-BMY-beats-Neck-and-throat-cancer-in-clinical-trial

User Image chickpea598 Posted - 4 hours ago

$BMY this looks like it will make another leg lower. $50 would make this a steal if it gets there.👍

User Image covence Posted - 5 hours ago

$PPBT did $BMY buy us yet? Just checking in.

User Image Trubach Posted - 5 hours ago

$AUPH $BMY hit 52 wk low today. Market doesn’t like their performance I guess. They have plenty plenty cash and needs to spend money for blockbuster drug. They should buy AUPH.

User Image cctranscripts Posted - 6 hours ago

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm https://conferencecalltranscripts.com/summary/?id=315544&pr=true $BMY

User Image cctranscripts Posted - 6 hours ago

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bristol-Myers Squibb Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm https://conferencecalltranscripts.com/summary/?id=315542&pr=true $BMY

User Image FrnkTss Posted - 6 hours ago

$BMY ww bounce bounce baby

User Image Iam4our Posted - 6 hours ago

$BMY Wait three days minimum for entry after ER.. $72 PT

User Image LockStocksandBarrel Posted - 6 hours ago

$BMY BMY needs to make a move…their pipeline is dogshit compared to other BP. Merk has been murking them for the past 3 years. Buy $AUPH for $6B and get your shit together.

User Image ChartMill Posted - 7 hours ago

$BENE and $BMY all in the Weinstein stage 1 setup phase according to our stock screener. https://www.chartmill.com/stock/stock-screener?sid=96&f=p_pg10,v1_50b500,atrpct_a_1,we1,wsl_a_30,exch_us&v=3&type=CANDLES&timeframe=WEEKLY&months=0.05&o1=2&o2=3&op2=30%252C255,255&width=1000&i1=81&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_Weinstein_Stage_1_Setups,&utm_campaign=social_tracking

User Image SweepCast Posted - 7 hours ago

SweepCast alerted: $BMY with Unusual Options Activity Alerted on $60 PUT Expiring: 11-19-2021 worth 29K🐻 |🥇 Start Using SweepCast! https://www.sweepcast.com/optionflow?symbol=BMY&name=PUT&strike=$60&type=TRADE&pre=$29K&exp=11-19-2021 🥇 |

User Image Theoriginalsa Posted - 8 hours ago

$AUPH $BMY $PFE Here was the Myokardia deal done last October. Very similar to Auph in my opinion.

User Image Theoriginalsa Posted - 8 hours ago

$AUPH $BMY https://seekingalpha.com/amp/article/4377762-bristol-myers-squibb-surprises-13-billion-cv-takeover Look to past deals for the guidance. Myokardia deal was last October for 13 billion. Lead drug estimated peak sales were 2 billion. Voclosporin is very close to that with estimates at 1-2 billion. Less than $50 pps is not gonna happen.

User Image Magnificient Posted - 8 hours ago

$AUPH $BMY needs a sucess, Asap! And Lupkynis is the solution. Hakuna Matata

User Image bennyboybc Posted - 8 hours ago

$AUPH I really think that $BMY will acquire aurinia but if for some reason they haven’t got the acumen to invest wisely in this then I am 100% sure this whole news story will be bringing more interested parties to the table. There are many companies that this would be a great strategic fit for and also lots of BP need a ready made, approved and launched, derisked future blockbuster that has almost no competition for at least 5 years possibly longer and a 16 year patent. Seriously this ticks so many boxes for what many BP need. Just hope PG and the team can get to a good place on this given it’s a rare gem that many will want.

User Image wangdiddy Posted - 8 hours ago

$BMY they bought my domain name for 15k. Had no clue. I could have listed it for 1 million and they would have probably bought it, haha.

User Image KryptoKat_Bounce Posted - 8 hours ago

$AUPH I say we get that 1:1 stock deal and ride that sucker back up to the 70s thru $BMY

User Image bennyboybc Posted - 8 hours ago

$AUPH $BMY dropped today after the Q3 investor call and has pretty much their lowest share price in 16 months. I listened to it and there was a lot of open concerns from the analysts that BMY would not be able to plug their revenue gap that’s coming in large part from multiple myeloma. The CEO tried to reassure but the analysts are not believing it will happen and the share price dropped further today. BMY need to acquire some assets that will generate immediate, mid term and long term blockbuster solid revenue. They really need to get their hands on lupkynis. It’s ready for explosive growth and is a great strategic fit. I think the investors would welcome the CEO investing the large capital they have on hand for totally de risked near term growth opportunity. They will be foolish to not get lupkynis in my opinion.

User Image YouOnlyLiveTwice Posted - 8 hours ago

$BMY They will be going hunting soon …One company that checks all the boxes $RVMD leader in Precision Oncology

User Image Baroquenhorse Posted - 9 hours ago

$BMY anybody have a good site for tracking Drug pricing reform ? Tia.

User Image HowdoIGRAPH Posted - 9 hours ago


Analyst Ratings
Morgan Stanley Equal-Weight Oct 12, 21
Berenberg Buy Oct 11, 21
Barclays Equal-Weight Oct 8, 21
Morgan Stanley Equal-Weight Jul 29, 21
Morgan Stanley Equal-Weight Apr 30, 21
Truist Securities Buy Apr 13, 21
Mizuho Buy Nov 17, 20
Societe Generale Buy Nov 16, 20
Truist Securities Hold Oct 23, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Option 48.03 52,213 2,507,790 98,355 11/23/20
VESSEY RUPERT EVP, Research & Earl.. EVP, Research & Early Dev. Nov 23 Sell 61.28 57,591 3,529,176 51,343 11/23/20